Ondansetron

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: A04AA01

Side effects

Options: Show MedDRA Preferred Terms, display only 20 labels

Side effect	Data for drug	Placebo	Labels
			1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38
Wound	10.6% - 27.6%	11.8% - 30.5%					x	x								x	x		x	x	x	x	x	x	x	x												x	x	x
Drowsiness	5.43% - 20.4%	6.76% - 23%					x	x								x	x		x	x	x	x	x	x	x	x		x	x	x	x	x	x	x	x	x	x	x	x	x
Headache	very common, 5.83% - 27.2%	5.08% - 15%	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Musculoskeletal pain	10.4%	10.8%																																				x	x	x
Fatigue	2.29% - 13.2%	2.29% - 5.48%																x	x	x	x	x	x	x	x	x												x	x	x
Malaise	2.29% - 13.2%	2.29% - 5.48%														x	x	x	x	x	x	x	x	x		x												x	x	x
Hypoxia	8.91%	6.59%					x	x										x	x	x	x	x	x	x	x	x
Body temperature increased	1.83% - 8.18%	1.1% - 6.4%	x	x			x	x										x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Genital disorder female	6.55%	6.21%																x	x	x	x	x	x	x	x	x
Constipation	common, 0.382% - 9.09%	0.382%	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Anxiety	2.01% - 6.49%	2.93% - 6.43%					x	x								x	x	x	x	x	x	x	x	x	x	x												x	x	x
Agitation	2.01% - 6.49%	2.93% - 6.43%					x	x										x	x	x	x	x	x	x	x	x												x	x	x
Bradycardia	postmarketing — 5.82%	5.65%			x	x	x	x	x	x	x	x	x	x	x				x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Dizziness	postmarketing — 0.01% - 12.2%	4.58% - 16.1%			x	x	x	x		x	x	x	x	x	x			x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Shivering	5.09% - 6.95%	5.65% - 7.13%					x	x								x	x		x	x	x	x	x	x	x	x												x	x	x
Urinary retention	3.11% - 5.09%	2.74% - 3.39%					x	x										x	x	x	x	x	x	x	x	x												x	x	x
Dry mouth	common						x	x	x	x	x	x	x	x	x
Burning rectal	common							x
Sensation of warmth	common				x	x	x	x
Hypotension	postmarketing — 1.83% - 4.91%	2.19% - 6.03%	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Pruritus	1.65% - 4.91%	0.548% - 3.77%					x	x										x	x	x	x	x	x	x	x	x		x	x	x	x	x	x	x	x	x	x	x	x	x
Diarrhoea	1.79% - 44%	0.898% - 18%	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Injection site reaction	common, 3.84%	3.29%			x	x	x	x																				x	x	x	x	x	x	x	x	x	x	x	x	x
Chest pain	postmarketing — 2.19%	2.74%	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Dysuria	2.01%	1.65%					x	x																														x	x	x
Paraesthesia	1.65%	0.366%																										x	x	x	x	x	x	x	x	x	x	x	x	x
Feeling cold	1.65%	1.46%																										x	x	x	x	x	x	x	x	x	x	x	x	x
Post procedural pain	1.19%	1.8%																																				x		x
Dyskinesia	uncommon				x	x	x	x	x					x	x
Movement disorder	uncommon				x	x	x	x	x					x	x
Convulsion	uncommon				x	x	x	x	x	x	x	x	x	x	x
Warmth	1%								x	x	x	x	x	x	x
Raised liver function tests	postmarketing, uncommon						x		x	x	x	x	x	x	x
Anaphylactic shock	postmarketing, rare				x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x									x	x	x	x	x
Angina pectoris	postmarketing		x	x					x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Angioedema	postmarketing								x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Arrhythmia	postmarketing, uncommon				x	x	x	x	x	x	x	x	x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Atrial fibrillation	postmarketing								x	x	x	x	x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Bronchospasm	postmarketing, 0.595%	1.8%					x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Neoplasm malignant	postmarketing																															x	x	x	x	x	x
Cardiovascular disorder	postmarketing								x	x	x	x	x	x	x
Dyspnoea	postmarketing															x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Toxic epidermal necrolysis	very rare, postmarketing					x			x					x	x										x	x										x	x
Eye disorder	postmarketing				x	x	x	x	x	x	x	x	x	x	x		x	x			x	x	x	x	x	x	x		x	x	x	x	x	x	x	x	x	x	x	x
Flushing	postmarketing, common				x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Hiccups	postmarketing, uncommon				x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Hypersensitivity	postmarketing								x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Type I hypersensitivity	rare				x	x	x	x	x	x	x	x	x	x	x
Laryngeal oedema	postmarketing								x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Laryngospasm	postmarketing						x	x	x		x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Mediastinal disorder	postmarketing				x	x	x	x	x	x	x	x	x	x	x
Myocardial infarction	postmarketing								x	x	x	x	x	x	x
Nervous system disorder	postmarketing				x	x	x	x	x	x	x	x	x	x	x
Pain	postmarketing, 2.19%	2.93%					x	x					x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Palpitations	postmarketing								x	x	x	x	x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Shock	postmarketing															x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Stevens-Johnson syndrome	postmarketing								x					x	x										x	x										x	x
Stridor	postmarketing								x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Syncope	postmarketing								x	x	x	x	x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Supraventricular tachycardia	postmarketing								x	x	x	x	x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Torsade de pointes	rare					x	x	x
Tremor	postmarketing								x	x	x	x	x	x	x
Urticaria	postmarketing								x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Angiopathy	rare				x	x	x	x
Vomiting	postmarketing											x
Hepatic failure	postmarketing								x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Oculogyric crisis	postmarketing, uncommon				x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Ventricular extrasystoles	postmarketing								x	x	x	x	x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Myocardial ischaemia	postmarketing								x	x	x	x	x	x	x
Opisthotonus	postmarketing								x	x	x	x	x	x	x
Orofacial dyskinesia	postmarketing								x	x	x	x	x	x	x
Accommodation disorder	postmarketing																										x	x	x	x	x	x	x	x	x	x	x	x	x	x
Blindness transient	very rare, postmarketing				x	x	x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Atrioventricular block second degree	postmarketing								x	x	x	x	x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Hepatobiliary disease	postmarketing				x	x	x	x	x	x	x	x	x	x	x
Redness	postmarketing												x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Vision blurred	postmarketing				x	x	x	x		x	x	x	x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Blindness	postmarketing				x	x	x	x	x	x	x	x	x	x	x
Electrocardiogram ST segment depression	postmarketing, uncommon				x	x	x	x	x	x	x	x	x	x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x
Nausea postoperative	postmarketing											x
Injection site burning	postmarketing																										x	x	x	x	x	x	x	x	x	x	x	x	x	x
Dystonic reaction	postmarketing — 0% - 5%	0%	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Visual disturbance	rare				x	x	x	x		x	x	x	x	x	x
Cardio-respiratory arrest	postmarketing								x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x		x	x
Local reaction	postmarketing						x	x					x	x	x												x		x	x	x	x	x	x	x	x	x	x	x	x
Electrocardiogram QT corrected interval prolonged	rare					x	x	x
Lymphocyte transformation test positive	postmarketing																											x	x	x	x	x	x	x	x	x	x
Toxic skin eruption	very rare					x
Abdominal pain							x	x	x	x	x	x	x	x	x
Asthenia									x	x	x	x	x	x	x
Asthma							x	x
Cough							x	x
Ear disorder							x	x
Rash			x	x			x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Flatulence							x	x
Gastrointestinal disorder					x	x	x	x
Cardiac disorder					x	x	x	x
Haemorrhage							x	x
Hypokalaemia			x	x					x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Immune system disorder					x	x	x	x
Liver disorder			x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Sleep disturbance							x	x
Swelling							x	x
Tachycardia			x	x					x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Urinary tract infection							x	x
Aspartate aminotransferase increased									x	x	x	x	x	x	x
Unspecified disorder of skin and subcutaneous tissue						x
Anaphylactoid reaction																x	x		x	x	x	x	x	x	x	x	x											x	x	x
Akathisia	0% - 6%	0%	x	x																							x												x	x
Tonic-clonic seizures			x	x												x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

Indication	Labels
Nausea	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x			x	x	x
Nausea postoperative			x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x	x	x	x	x			x	x	x
Neoplasm malignant	x	x			x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
Vomiting	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x			x	x	x

Side effects:	14
Source:	FDA Structured Product Label

Side effects:	14
Source:	FDA Structured Product Label

Side effects:	31
Source:	Medsafe

Side effects:	36
Source:	Medsafe

Side effects:	59
Source:	medicines.org.au

Side effects:	59
Source:	medicines.org.au

Side effects:	55
Source:	Health Canada

Side effects:	53
Source:	Health Canada

Side effects:	54
Source:	Health Canada

Side effects:	56
Source:	Health Canada

Side effects:	57
Source:	Health Canada

Side effects:	61
Source:	Health Canada

Side effects:	61
Source:	Health Canada

Side effects:	34
Source:	FDA Structured Product Label

Side effects:	35
Source:	FDA Structured Product Label

Side effects:	39
Source:	FDA Structured Product Label

Side effects:	42
Source:	FDA

Side effects:	43
Source:	FDA Structured Product Label

Side effects:	44
Source:	FDA Structured Product Label

Side effects:	44
Source:	FDA Structured Product Label

Side effects:	44
Source:	FDA Structured Product Label

Side effects:	44
Source:	FDA Structured Product Label

Side effects:	45
Source:	FDA Structured Product Label

Side effects:	46
Source:	FDA Structured Product Label

Side effects:	48
Source:	FDA Structured Product Label

Side effects:	49
Source:	FDA Structured Product Label

Side effects:	51
Source:	FDA Structured Product Label

Side effects:	51
Source:	FDA Structured Product Label

Side effects:	51
Source:	FDA Structured Product Label

Side effects:	52
Source:	FDA Structured Product Label

Side effects:	52
Source:	FDA Structured Product Label

Side effects:	52
Source:	FDA Structured Product Label

Side effects:	52
Source:	FDA Structured Product Label

Side effects:	55
Source:	FDA Structured Product Label

Side effects:	55
Source:	FDA Structured Product Label

Side effects:	61
Source:	FDA Structured Product Label

Side effects:	62
Source:	FDA Structured Product Label

Side effects:	63
Source:	FDA Structured Product Label

Color scheme:

standard – alternative

		100%
		75%
		50%
		10%
		frequent (1% to 100%)
		infrequent (0.1% to 1%)
		rare (<0.1%)
		postmarketing
		0%
		no frequency information
		not found on label

Search results :

Ondansetron

Side effects

Indications

Color scheme: